Nevertheless, MCC expression of FOLH1 is significantly more common than the observed expression of human epidermal growth factor receptor‐2 (HER‐2) in breast cancer (16%; 95% CI, 12%, 21%),43 and than the reported ∼49% PD‐L1 and ∼55% PD‐1 expression on MCC tumour cells and infiltrating lymphocytes, respectively.12 The gene discussed is FOLH1; the disease is neoplasm.